BerGenBio Logo (WIPO, 22.10.2021)
WIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Internationale Marke BerGenBio wurde als Bildmarke am 22.10.2021 bei der Weltorganisation für geistiges Eigentum angemeldet.
Logodesign (Wiener Klassifikation)
#Verschiedene geometrische Figuren, nebeneinander, verbunden oder sich überschneidend #Briefe, die eine besondere Form des Schreibens darstellen #Farben #Kreis oder Ellipsen mit einem oder mehreren anderen Polygonen #Briefe, die von einem Zeichen unverhältnismäßiger Größe überragt werden #Zwei vorherrschende Farben
| Markenform | Bildmarke |
| Aktenzeichen | 1637799 |
| Registernummer | 317770 |
| Länder | 
|
| Basismarke |
Nr. 317770,
23. September 2021
|
| Anmeldedatum | 22. Oktober 2021 |
| Ablaufdatum | 22. Oktober 2031 |
Markeninhaber
P.O. Box 2324 Møllendal
N-5867 Bergen
NO
N-5867 Bergen
NO
Markenvertreter
Aurora Building,
Counterslip
GB
Waren und Dienstleistungen
01
Chemicals, chemical compounds, biochemicals and biologic
compounds for scientific or industrial purposes, or for use
in laboratories or in research; chemicals, chemical
compounds, biochemicals and biologic compounds for
analytical and diagnostic purposes in laboratory use;
chemicals, chemical compounds, biochemicals and biologic
compounds for the experimental production of drugs,
pharmaceutical products and biotechnological preparations;
chemicals, chemical compounds, biochemicals and biologic
compounds for use in the development and manufacture of
diagnostic products and services, drugs and pharmaceutical
products, including for the diagnosis and treatment of
cancers, including lung cancer, leukaemia, aggressive
cancers, immune evasive cancers and metastatic cancers;
chemicals, chemical compounds, biochemicals and biologic
compounds for use in the development and manufacture of
drugs and pharmaceutical products, including drugs and
pharmaceutical products that target axl, akt3 or other
genes, proteins, kinases and enzymes; active chemical and
biochemical ingredients and components for use in the
development and manufacture of diagnostic products and
services, drugs and pharmaceutical products, including for
the diagnosis and treatment of cancers, including lung
cancer, leukaemia, aggressive cancers, immune evasive
cancers and metastatic cancers; antibodies, small molecules
and proteins for scientific or industrial purposes, or for
use in laboratories or in research; antibodies, small
molecules and proteins for use in the development and
manufacture of diagnostic products and services, drugs and
pharmaceutical products, including for the diagnosis and
treatment of cancers, including lung cancer, leukaemia,
aggressive cancers, immune evasive cancers and metastatic
cancers; antibodies, small molecules and proteins for use in
the development and manufacture of drugs and pharmaceutical
products, including drugs and pharmaceutical products that
target axl, akt3 or other genes, proteins, kinases and
enzymes; antibodies, anti-axl antibodies, small molecules,
small molecules that inhibit axl kinase, selective
inhibitors, selective axl inhibitors, selective axl kinase
inhibitors and selective inhibitors of cell surface proteins
for scientific or industrial purposes, or for use in
laboratories or in research; antibodies, anti-axl
antibodies, small molecules, small molecules that inhibit
axl kinase, selective inhibitors, selective axl inhibitors,
selective axl kinase inhibitors and selective inhibitors of
cell surface proteins for use in the development and
manufacture of diagnostic products and services, drugs and
pharmaceutical products, including for the diagnosis and
treatment of cancers, including lung cancer, leukaemia,
aggressive cancers, immune evasive cancers and metastatic
cancers; antibodies, anti-axl antibodies, small molecules,
small molecules that inhibit axl kinase, selective
inhibitors, selective axl inhibitors, selective axl kinase
inhibitors and selective inhibitors of cell surface proteins
for use in the development and manufacture of drugs and
pharmaceutical products, including drugs and pharmaceutical
products that target axl, akt3 or other genes, proteins,
kinases and enzymes; proteins for use in kinase inhibiting
technology [other than for medical use]
05
Drugs for medical purposes, drugs and pharmaceutical
products; drugs for medical purposes, drugs and
pharmaceutical products incorporating antibodies, anti-axl
antibodies, small molecules, small molecules that inhibit
axl kinase, selective inhibitors, selective axl inhibitors,
selective axl kinase inhibitors, or selective inhibitors of
cell surface proteins; drugs for medical purposes, drugs and
pharmaceutical products, including for treatment of cancers,
including lung cancer, leukaemia, aggressive cancers, immune
evasive cancers and metastatic cancers; drugs and
pharmaceutical products including drugs and pharmaceutical
products that target axl, akt3 or other genes, proteins,
kinases and enzymes; drugs and pharmaceutical products for
use in oncology; chemicals, chemical compounds, biochemicals
and biologic compounds for medical purposes; diagnostic test
kits for medical laboratory analysis; diagnostic kits for
use in disease testing; antibodies, small molecules and
proteins for medical purposes; antibodies, anti-axl
antibodies, small molecules, small molecules that inhibit
axl kinase, selective inhibitors, selective axl inhibitors,
selective axl kinase inhibitors and selective inhibitors of
cell surface proteins for medical purposes; protein
synthesis inhibitors
42
Drug discovery and drug development services; scientific
research services; research and development services in the
fields of oncology and immunology; scientific research
services related to the role of axl and related kinase
signalling in disease; scientific research services related
to axl biology and its role in mediating aggressive disease;
scientific research services related to biomarker discovery;
scientific services related to the development of diagnostic
products and services, including relating to the treatment
of cancers, including lung cancer, leukaemia, aggressive
cancers, immune evasive cancers and metastatic cancers;
scientific research services related to improving the
efficacy of chemotherapy, targeted cancer therapy and
immuno-oncology drugs; research and development services in
the field of antibodies, small molecules and proteins;
conducting or providing research and development services
for others in the field of antibody and small molecule
technology; medical and biotechnology research services;
research, development and engineering of antibodies, small
molecules and proteins, including anti-axl antibodies, small
molecules that inhibit axl kinase, selective inhibitors,
selective axl inhibitors, selective axl kinase inhibitors
and selective inhibitors of cell surface proteins;
laboratory services relating to the production of
antibodies, small molecules and proteins, including anti-axl
antibodies, small molecules that inhibit axl kinase,
selective inhibitors, selective axl inhibitors, selective
axl kinase inhibitors and selective inhibitors of cell
surface proteins; researching and developing the use of
antibodies, small molecules and proteins for the treatment
of patients; information, consultancy and advisory services
related to the aforesaid
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
Markenhistorie
| Datum | Belegnummer | Bereich | Eintrag |
|---|---|---|---|
| 28. Juni 2023 | 2023/27 Gaz | KR | Ablehnung |
| 04. Mai 2023 | 2023/18 Gaz | CA | Ablehnung |
| 02. Februar 2023 | 2023/7 Gaz | IL | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 18. Januar 2023 | 2023/3 Gaz | KR | Ablehnung |
| 04. Januar 2023 | 2023/1 Gaz | US | Ablehnung |
| 22. Dezember 2022 | 2022/51 Gaz | JP | Ablehnung |
| 08. Dezember 2022 | 2022/49 Gaz | CH | Ablehnung |
| 19. September 2022 | 2022/50 Gaz | SG | Ablehnung |
| 08. September 2022 | 2022/36 Gaz | MX | Ablehnung |
| 26. Mai 2022 | 2022/21 Gaz | EM | Ablehnung |
| 25. Mai 2022 | 2022/22 Gaz | IL | Ablehnung |
| 06. Mai 2022 | 2022/19 Gaz | CN | Ablehnung |
| 04. April 2022 | 2022/14 Gaz | GB | Ablehnung |
| 29. März 2022 | 2022/13 Gaz | AU | Ablehnung |
| 24. Januar 2022 | 2022/5 Gaz | IN | Ablehnung |
| 22. Oktober 2021 | 2021/51 Gaz | NO | Eintragung |
ID: 141637799